12:00 , May 20, 2019 |  BioCentury  |  Emerging Company Profile

Reneo: Small molecules for rare mitochondrial diseases

With a $50 million series A led by NEA and a management team guided by veterans of Shire takeout Lumena, Reneo believes its small molecule could carve out a niche in the rare genetic mitochondrial...
12:02 , Mar 25, 2019 |  BC Extra  |  Financial News

Arch Oncology raises $50M series B to develop anti-CD47 mAb

Backed by new investor Lightchain, Arch Oncology raised $50 million in a series B round to enable the company to advance its anti-CD47 mAb, AO-176, which is in a Phase I trial to treat solid...
20:08 , Dec 21, 2018 |  BC Week In Review  |  Financial News

RiverVest closes fourth life science venture fund

RiverVest Venture Partners announced the final close of RiverVest Venture Fund IV at $184.4 million. The firm has invested in eight companies from the fund to date, including cancer company OncoResponse Inc. (Houston, Texas) and...
21:04 , Dec 18, 2018 |  BC Extra  |  Financial News

RiverVest closes new fund at $184.4M

RiverVest Venture Partners announced the final close of RiverVest Venture Fund IV at $184.4 million. The firm has invested in eight companies from the fund to date, including cancer company OncoResponse Inc. (Houston, Texas) and...
18:44 , Nov 9, 2018 |  BC Week In Review  |  Company News

Mirum launches with liver disease candidates from Shire

Mirum Pharmaceuticals Inc. (San Francisco, Calif.) launched with a $120 million series A round and a license from Shire plc (LSE:SHP; NASDAQ:SHPG) to a pair of candidates to treat liver diseases. The start-up intends to...
18:33 , Nov 7, 2018 |  BC Extra  |  Financial News

Mirum launches with liver disease candidates from Shire

Mirum Pharmaceuticals Inc. (San Francisco, Calif.) launched with a $120 million series A round and a license from Shire plc (LSE:SHP; NASDAQ:SHPG) to a pair of candidates to treat liver diseases. The start-up intends to...
17:25 , Sep 14, 2018 |  BC Week In Review  |  Financial News

OncoResponse to move into clinic with $40M series B

OncoResponse Inc. (Houston, Texas) raised $40 million in a series B round led by RiverVest Venture Partners. Fellow new investors Qatar Investment Authority and Redmile Group participated, as did existing investors Alexandria Venture Investments, Arch...
22:22 , Sep 11, 2018 |  BC Extra  |  Financial News

OncoResponse to move into clinic with $40M series B

OncoResponse Inc. (Houston, Texas) raised $40 million in a series B round led by RiverVest Venture Partners. Fellow new investors Qatar Investment Authority and Redmile Group participated, as did existing investors Alexandria Venture Investments, Arch...
17:12 , Jul 20, 2018 |  BC Week In Review  |  Financial News

Allakos spikes after pricing upsized IPO above range

Allakos Inc. (NASDAQ:ALLK) gained $13.25 (74%) to $31.25 July 19 after it raised $128.4 million through the sale of 7.1 million shares at $18 in an upsized IPO. Goldman Sachs, Jefferies and William Blair are...
14:27 , Jul 19, 2018 |  BC Extra  |  Financial News

Allakos spikes after pricing upsized IPO above range

Allakos Inc. (NASDAQ:ALLK) gained $13.25 (74%) to $31.25 Thursday after it raised $128.4 million through the sale of 7.1 million shares at $18 in an upsized IPO. Goldman Sachs, Jefferies and William Blair are underwriters....